Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 241098, 9 pages
http://dx.doi.org/10.1155/2015/241098
Clinical Study

Effluent Tenascin-C Levels Reflect Peritoneal Deterioration in Peritoneal Dialysis: MAJOR IN PD Study

Division of Nephrology, Department of Internal Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan

Received 22 May 2015; Revised 4 September 2015; Accepted 29 October 2015

Academic Editor: Robert Beelen

Copyright © 2015 Ichiro Hirahara et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. C. Gandhi, H. M. Humayun, T. S. Ing et al., “Sclerotic thickening of the peritoneal membrane in maintenance peritoneal dialysis patients,” Archives of Internal Medicine, vol. 140, no. 9, pp. 1201–1203, 1980. View at Publisher · View at Google Scholar · View at Scopus
  2. D. W. Schmidt and M. F. Flessner, “Pathogenesis and treatment of encapsulating peritoneal sclerosis: basic and translational research,” Peritoneal Dialysis International, vol. 28, supplement 5, pp. S10–S15, 2008. View at Google Scholar · View at Scopus
  3. Y. Kawaguchi, A. Saito, H. Kawanishi et al., “Recommendations on the management of encapsulating peritoneal sclerosis in Japan, 2005: diagnosis, predictive markers, treatment, and preventive measures,” Peritoneal Dialysis International, vol. 25, supplement 4, pp. S83–S95, 2005. View at Google Scholar · View at Scopus
  4. Working Group Committee for the Preparation of Guidelines for Peritoneal Dialysis, “Japanese Society for Dialysis Therapy. 2009 Japanese society for dialysis therapy guidelines for peritoneal dialysis,” Therapeutic Apheresis Dialysis, vol. 14, no. 6, pp. 489–504, 2010. View at Google Scholar
  5. R. Yamamoto, Y. Otsuka, M. Nakayama et al., “Risk factors for encapsulating peritoneal sclerosis in patients who have experienced peritoneal dialysis treatment,” Clinical & Experimental Nephrology, vol. 9, no. 2, pp. 148–152, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. Z. J. Twardowski, K. D. Nolph, R. Khanna et al., “Peritoneal equilibration test,” Peritoneal Dialysis Bulletin, vol. 7, no. 3, pp. 138–147, 1987. View at Google Scholar · View at Scopus
  7. I. Hirahara, M. Inoue, K. Okuda, Y. Ando, S. Muto, and E. Kusano, “The potential of matrix metalloproteinase-2 as a marker of peritoneal injury, increased solute transport, or progression to encapsulating peritoneal sclerosis during peritoneal dialysis—a multicentre study in Japan,” Nephrology Dialysis Transplantation, vol. 22, no. 2, pp. 560–567, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. I. Hirahara, M. Inoue, T. Umino, O. Saito, S. Muto, and E. Kusano, “Matrix metalloproteinase levels in the drained dialysate reflect the peritoneal solute transport rate: a multicentre study in Japan,” Nephrology Dialysis Transplantation, vol. 26, no. 5, pp. 1695–1701, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. D. L. Barreto, A. M. Coester, D. G. Struijk, and R. T. Krediet, “Can effluent matrix metalloproteinase 2 and plasminogen activator inhibitor 1 be used as biomarkers of peritoneal membrane alterations in peritoneal dialysis patients?” Peritoneal Dialysis International, vol. 33, no. 5, pp. 529–537, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. M. M. Zweers, D. R. de Waart, W. Smit, D. G. Struijk, and R. T. Krediet, “Growth factors VEGF and TGF-β1 in peritoneal dialysis,” The Journal of Laboratory and Clinical Medicine, vol. 134, no. 2, pp. 124–132, 1999. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Kaku, K. Nohara, Y. Tsutsumi et al., “The relationship among the markers of peritoneal function such as PET, MMP-2, IL-6 etc, in pediatric and adolescent PD patients,” Jin To Touseki, vol. 57, supplement, pp. 296–298, 2004. View at Google Scholar
  12. I. Hirahara, E. Kusano, S. Yanagiba et al., “Peritoneal injury by methylglyoxal in peritoneal dialysis,” Peritoneal Dialysis International, vol. 26, no. 3, pp. 380–392, 2006. View at Google Scholar · View at Scopus
  13. I. Hirahara, Y. Ishibashi, S. Kaname, E. Kusano, and T. Fujita, “Methylglyoxal induces peritoneal thickening by mesenchymal-like mesothelial cells in rats,” Nephrology Dialysis Transplantation, vol. 24, no. 2, pp. 437–447, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. I. Hirahara, H. Sato, T. Imai et al., “Methylglyoxal induced basophilic spindle cells with podoplanin at the surface of peritoneum in rat peritoneal dialysis model,” BioMed Research International, vol. 2015, Article ID 289751, 7 pages, 2015. View at Publisher · View at Google Scholar
  15. S. Osada, C. Hamada, T. Shimaoka, K. Kaneko, S. Horikoshi, and Y. Tomino, “Alterations in proteoglycan components and histopathology of the peritoneum in uraemic and peritoneal dialysis (PD) patients,” Nephrology Dialysis Transplantation, vol. 24, no. 11, pp. 3504–3512, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Yáñez-Mó, E. Lara-Pezzi, R. Selgas et al., “Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells,” The New England Journal of Medicine, vol. 348, no. 5, pp. 403–413, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Aguilera, M. Yáñez-Mo, R. Selgas, F. Sánchez-Madrid, and M. López-Cabrera, “Epithelial to mesenchymal transition as a triggering factor of peritoneal membrane fibrosis and angiogenesis in peritoneal dialysis patients,” Current Opinion in Investigational Drugs, vol. 6, no. 3, pp. 262–268, 2005. View at Google Scholar · View at Scopus
  18. G. del Peso, J. A. Jiménez-Heffernan, M. A. Bajo et al., “Epithelial-to-mesenchymal transition of mesothelial cells is an early event during peritoneal dialysis and is associated with high peritoneal transport,” Kidney International, vol. 73, supplement, pp. S26–S33, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Imanaka-Yoshida, M. Hiroe, Y. Yasutomi et al., “Tenascin-C is a useful marker for disease activity in myocarditis,” The Journal of Pathology, vol. 197, no. 3, pp. 388–394, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Nagaharu, X. Zhang, T. Yoshida et al., “Tenascin C induces epithelial-mesenchymal transition-like change accompanied by SRC activation and focal adhesion kinase phosphorylation in human breast cancer cells,” American Journal of Pathology, vol. 178, no. 2, pp. 754–763, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Katoh, K. Nagaharu, N. Shimojo et al., “Binding of αvβ1 and αvβ6 integrins to tenascin-C induces EMT like change of breast cancer cell,” Oncogenesis, vol. 19, no. 2, p. e65, 2013. View at Google Scholar
  22. C. B. Nilsson-Thorell, N. Muscalu, A. H. G. Andren, P. T. T. Kjellstrand, and A. P. Wieslander, “Heat sterilization of fluids for peritoneal dialysis gives rise to aldehydes,” Peritoneal Dialysis International, vol. 13, no. 3, pp. 208–213, 1993. View at Google Scholar · View at Scopus
  23. A. P. Wieslander, R. Deppisch, E. Svensson, G. Forsback, R. Speidel, and B. Rippe, “In vitro biocompatibility of a heat-sterilized, low-toxic, and less acidic fluid for peritoneal dialysis,” Peritoneal Dialysis International, vol. 15, no. 3, pp. 158–164, 1995. View at Google Scholar · View at Scopus
  24. K. N. Lai, J. C. K. Leung, L. Y. Y. Chan et al., “Differential expression of receptors for advanced glycation end-products in peritoneal mesothelial cells exposed to glucose degradation products,” Clinical & Experimental Immunology, vol. 138, no. 3, pp. 466–475, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. E.-J. Oh, H.-M. Ryu, S.-Y. Choi et al., “Impact of low glucose degradation product bicarbonate/lactate-buffered dialysis solution on the epithelial-mesenchymal transition of peritoneum,” American Journal of Nephrology, vol. 31, no. 1, pp. 58–67, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Liu, N. Zhang, and D. Tian, “MiR-30b is involved in methylglyoxal-induced epithelial-mesenchymal transition of peritoneal mesothelial cells in rats,” Cellular & Molecular Biology Letters, vol. 19, no. 2, pp. 315–329, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. W. Che, M. Asahi, M. Takahashi et al., “Selective induction of heparin-binding epidermal growth factor-like growth factor by methylglyoxal and 3-deoxyglucosone in rat aortic smooth muscle cells: the involvement of reactive oxygen species formation and a possible implication for atherogenesis in diabetes,” The Journal of Biological Chemistry, vol. 272, no. 29, pp. 18453–18459, 1997. View at Publisher · View at Google Scholar · View at Scopus
  28. S. W. Stoll, L. Rittié, J. L. Johnson, and J. T. Elder, “Heparin-binding EGF-like growth factor promotes epithelial-mesenchymal transition in human keratinocytes,” Journal of Investigative Dermatology, vol. 132, no. 9, pp. 2148–2157, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Nakayama, A. Sakai, M. Numata, and T. Hosoya, “Hyper-vascular change and formation of advanced glycation endproducts in the peritoneum caused by methylglyoxal and the effect of an anti-oxidant, sodium sulfite,” American Journal of Nephrology, vol. 23, no. 6, pp. 390–394, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. V. Schwenger, C. Morath, A. Salava et al., “Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products,” Journal of the American Society of Nephrology, vol. 17, no. 1, pp. 199–207, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. A. S. De Vriese, R. G. Tilton, S. Mortier, and N. H. Lameire, “Myofibroblast transdifferentiation of mesothelial cells is mediated by RAGE and contributes to peritoneal fibrosis in uraemia,” Nephrology Dialysis Transplantation, vol. 21, no. 9, pp. 2549–2555, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Cai, K. Onoda, M. Takao et al., “Degradation of tenascin-C and activity of matrix metalloproteinase-2 are associated with tumor recurrence in early stage non-small cell lung cancer,” Clinical Cancer Research, vol. 8, no. 4, pp. 1152–1156, 2002. View at Google Scholar · View at Scopus
  33. J. Chen, Z. Chen, M. Chen et al., “Role of fibrillar tenascin-C in metastatic pancreatic cancer,” International Journal of Oncology, vol. 34, no. 4, pp. 1029–1036, 2009. View at Publisher · View at Google Scholar · View at Scopus